Industry / Israel
BMI Looks At Teva
September 2007 | BMI ViewIn the wake of mixed news on the regulatory and R&D fronts, banking analysts seem divided over the prospects for Israel's Teva Pharmaceutical Industries. Analysts at JP Morgan chose to maintain their 'neutral' rating on the company, whereas Cowen & Co. stuck with its 'outperform' rating, demonstrating the differing opinions coming out of major financial institutions. Here, BMI gives its own view on the health of the world's largest generics
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
